AKTOCYTE Set To Transform Cancer Care

  • Towards enhancing the quality of life for cancer patients undergoing radiotherapy.
  • Scientists from Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru have joined hands to develop AKTOCYTE tablets.
  • Experts from Bhabha Atomic Research Centre, Mumbai; Tata Memorial Hospital, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai collaborated with the IDRS Labs.
  • It has received approval from the Food Safety and Standards Authority of India (FSSAI), operating under the Ministry of Health & Family Welfare, Government of India.


  • It has demonstrated exceptional efficacy in pelvic cancer patients undergoing radiotherapy, showcasing significant recovery and eliminating the need for surgical interventions.
  • The tablets serve as more than just a supplement.
  • AKTOCYTE is positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, showcasing its versatility in cancer care.
  • The approval by FSSAI underscores the commitment to safety and quality standards, providing healthcare professionals and patients confidence in the reliability of AKTOCYTE tablets.
  • Anticipated to hit the market in January 2024, AKTOCYTE tablets are poised to become a transformative addition to cancer treatment protocols.
Posted in Current Affairs.